Kanabo Group PLC - medical cannabis research and distribution of cannabis-derived products - Says its unique CBD and nicotine formula has advanced from Patent Cooperation Treaty phase to National Phase in the US, UK, and EU countries - the last phase before becoming an internationally approved patent. The formula is targeted at both the traditional smoking and e-cigarettes markets which are expected to reach GBP50 million over the coming years, it says.
Chief Executive Officer Avihu Tamir says: "Our unique patent pending CBD formulations and controlled and consistent delivery device, the VapePod, represents an excellent opportunity for governments to quickly end the reliance on tobacco for millions of citizens worldwide. Our tests show a dramatic reduction in nicotine consumption, whether in cigarettes or e-cigarettes, which can only be good news for health services around the world."
Current stock price: 12.50 pence
Year-to-date change: down 32%
By Arvind Bhunjun; arvindbhunjun@alliancenews.com
Copyright 2021 Alliance News Limited. All Rights Reserved.
